osteoporosis
Conditions
Interventions
Dexmedetomidine Group:Intravenous saline 5min before the start of surgery
Dexmedetomidine + Buprenorphine group:Intravenous injection of 0.02 mg/kg buprenorphine 5min before the start of surgery
Dexmedetomidine + nalbuphine group:Intravenous 0.1mg/kg nalbuphine 5min before the start of surgery
Dexmedetomidine + Pentazocine group:Intravenous injection of 0.4mg/kg pentazocine 5min before the start of surgery
Sponsors
Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)
Eligibility
Sex/Gender
All
Age
65 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1.Patients who underwent single vertebroplasty; 2.Age > 65 years; 3.ASA grade I-III; 4.BMI 18-28 kg/m2; 5.Signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients who are unable to complete the scale assessment; 2.Combined history of mental illness, chronic pain, alcohol or drug abuse; 3.Severe cardiac, pulmonary, hepatic, and renal function obvious abnormalities (transaminases elevated 2 times or more); 4.Allergy to experimental drugs; 5.Preoperative PaO2<60 mmHg or SpO2<92%; 6.Participation in another drug clinical study within the past 30 days;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS pain scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ramsay Sedation Score;systolic blood pressure;diastolic blood pressure;mean arterial pressure;heart rate;pulse oximetry;Number and dose of intraoperative vasoactive agents;Postoperative delirium (POD);Quality of post-operative recovery;Patient pain satisfaction;headaches and dizziness;nausea;vomiting;insomnia;urine retention;pruritus;low blood pressure;high blood pressure;tachycardia;bradycardia;arrhythmia;PACU dwell time;Date of discharge;First time on the ground; | — |
Countries
China
Contacts
Public ContactCongjie Bi
Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)
Outcome results
None listed